Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03412760
Other study ID # HydropsUCSF
Secondary ID 5K12HD001262
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date October 11, 2018
Est. completion date December 2025

Study information

Verified date January 2024
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a national, prospective study designed to investigate the genetic etiologies of non-immune hydrops fetalis (NIHF) and other birth defects. At least half of prenatally diagnosed NIHF cases remain of unknown etiology after standard work up, and a substantial proportion of other birth defects remain of unknown etiology as well. The investigators are performing exome sequencing (ES) for the affected fetus or neonate in unexplained cases, as well as enrolling cases with a genetic explanation to represent the full spectrum of diseases underlying NIHF and other birth defects.


Description:

Up to 1:1700 pregnancies are affected by non-immune hydrops fetalis (NIHF), and this condition is associated with significant perinatal risks ranging from preterm birth to Ballantyne (maternal mirror) syndrome, stillbirth, and neonatal death. Birth defects affect 1:33 pregnancies, and are the leading cause of infant death (contributing to approximately 20% of infant deaths). The investigators are performing exome sequencing (ES) for the affected fetus or neonate in unexplained cases, as well as enrolling cases with a genetic explanation to represent the full spectrum of diseases underlying NIHF and other birth defects. This study is open for enrollment by invitation. In addition to performing ES, the investigators are collecting clinical data prospectively on all cases of NIHF and other birth defects, including demographics, medical and obstetric history, prenatal and delivery course, and postnatal outcomes. The specific research aims include: 1. Create registry of clinical data for cases of NIHF and other birth defects. 2. Investigate genetic variants underlying NIHF and other birth defects via ES. 3. Characterize the features and outcomes of genetic diseases presenting with NIHF and other birth defects. - In particular, the researchers are focused on enrolling cases of increased nuchal translucency, cystic hygroma, abnormal fetal fluid collection (even single fluid compartments such as isolated pleural effusion), and/or frank NIHF. This research will contribute novel information about the frequency and types of genetic disorders in fetuses and newborns with a diagnosis of NIHF and other birth defects, enabling providers to more accurately counsel about prognosis and individualize perinatal care. This information will also facilitate informed decision-making for parents, allow the care team to anticipate specific perinatal needs, and enable more precise counseling for the parents about recurrence risks for NIHF and other birth defects. Further, the research will facilitate future aims such as novel fetal therapies for genetic diseases.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 500
Est. completion date December 2025
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Singletons or dichorionic twin pregnancies that are diagnosed prenatally with non-immune hydrops fetalis (NIHF) or another birth defect. Cases with chromosomal abnormalities, postnatal samples, and stillbirths will still be included. Exclusion Criteria: - Monochorionic twin pregnancies and cases of hydrops fetalis that are attributed to red cell alloimmunization (due to hydrops fetalis caused by different pathophysiologic processes).

Study Design


Intervention

Diagnostic Test:
Exome sequencing
Expansive genetic test performed for affected fetus or neonate.

Locations

Country Name City State
United States University of California, San Francisco San Francisco California

Sponsors (4)

Lead Sponsor Collaborator
University of California, San Francisco Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Fetal Health Foundation, National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Genetic variants detected with exome sequencing that implicate a genetic disease underlying non-immune hydrops fetalis (NIHF) and other birth defects. Both NIHF and birth defects can be caused by a variety of genetic variants that researchers are continuing to learn more about. Exome sequencing will yield information about the specific genetic variants present in cases of NIHF and other birth defects, and about the specific diseases implicated by these variants. Investigators will determine the proportion of cases seen in the setting of particular genetic variants, and will correlate phenotypic outcomes with specific genotypes. Turn around time for exome sequencing results is 2-4 weeks for ongoing pregnancies and live infants, and is 8-12 weeks for stillbirths, terminations, and infant demises.
See also
  Status Clinical Trial Phase
Completed NCT02965287 - Validation of a Test for Fetal Malformations
Completed NCT05527327 - Pannus Retraction for Ultrasound Evaluation of the Obese Gravida: A Pilot Study N/A
Completed NCT05655741 - Modified Delphi for Genomic Bereavement Care
Recruiting NCT05790473 - Artificial Intelligence Algorithm for the Screening of Abnormal Fetal Brain Findings at First Trimester Ultrasound Scan
Recruiting NCT03398629 - Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
Completed NCT05764408 - Pannus Assistance Needed for Obstetric Ultrasound Studies N/A
Recruiting NCT06410391 - Fetal Brain Ultrasound
Not yet recruiting NCT04897178 - Machine Learning-based Anomaly Recognition System
Completed NCT02664207 - Extended Criteria For Fetal Myelomeningocele Repair N/A
Completed NCT02875860 - 'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial Phase 2
Completed NCT05785338 - Trial Observationnal
Completed NCT03795857 - Antenatal Palliative Care
Completed NCT04174235 - Prevalence of Fetal Congenital Anomalies Among Pregnant Women Attending University Hospital
Completed NCT03544970 - An Audit of the Posterior Fossa Characterization in Open Spina Bifida Based on Tertiary Center Experience